Diamedica Therapeutics Stock Filter Stocks by Fundamentals

DMAC Stock  USD 2.65  0.07  2.57%   
DiaMedica Therapeutics fundamentals help investors to digest information that contributes to DiaMedica Therapeutics' financial success or failures. It also enables traders to predict the movement of DiaMedica Stock. The fundamental analysis module provides a way to measure DiaMedica Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to DiaMedica Therapeutics stock.
  
This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

DiaMedica Price to Earnings To Growth Analysis

DiaMedica Price to Earnings To Growth Driver Correlations

Understanding the fundamental principles of building solid financial models for DiaMedica Therapeutics is extremely important. It helps to project a fair market value of DiaMedica Stock properly, considering its historical fundamentals such as Price to Earnings To Growth. Since DiaMedica Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of DiaMedica Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of DiaMedica Therapeutics' interrelated accounts and indicators.
0.821.0-0.36-0.920.180.340.970.781.00.430.750.990.830.920.790.940.94
0.820.81-0.22-0.860.110.390.890.880.830.40.750.820.890.780.760.730.73
1.00.81-0.36-0.920.160.340.970.771.00.420.750.990.830.920.790.940.94
-0.36-0.22-0.360.270.04-0.72-0.32-0.13-0.360.07-0.56-0.35-0.16-0.47-0.19-0.39-0.38
-0.92-0.86-0.920.27-0.18-0.34-0.96-0.82-0.93-0.26-0.73-0.93-0.88-0.9-0.81-0.88-0.88
0.180.110.160.04-0.18-0.220.210.510.190.150.140.190.110.140.150.240.24
0.340.390.34-0.72-0.34-0.220.370.230.340.160.480.320.330.540.370.320.32
0.970.890.97-0.32-0.960.210.370.850.970.360.760.970.880.930.790.910.91
0.780.880.77-0.13-0.820.510.230.850.790.460.720.790.860.730.720.70.7
1.00.831.0-0.36-0.930.190.340.970.790.440.750.990.830.920.790.950.95
0.430.40.420.07-0.260.150.160.360.460.440.210.460.460.430.360.410.41
0.750.750.75-0.56-0.730.140.480.760.720.750.210.750.820.680.790.650.65
0.990.820.99-0.35-0.930.190.320.970.790.990.460.750.860.930.750.950.95
0.830.890.83-0.16-0.880.110.330.880.860.830.460.820.860.790.830.730.73
0.920.780.92-0.47-0.90.140.540.930.730.920.430.680.930.790.710.90.9
0.790.760.79-0.19-0.810.150.370.790.720.790.360.790.750.830.710.730.73
0.940.730.94-0.39-0.880.240.320.910.70.950.410.650.950.730.90.731.0
0.940.730.94-0.38-0.880.240.320.910.70.950.410.650.950.730.90.731.0
Click cells to compare fundamentals
Competition

DiaMedica Price Earnings To Growth Ratio

Price Earnings To Growth Ratio

(0.29)

At present, DiaMedica Therapeutics' Price Earnings To Growth Ratio is projected to slightly decrease based on the last few years of reporting.
Based on the latest financial disclosure, the price to earnings to growth indicator of DiaMedica Therapeutics is roughly 0.0null. This indicator is about the same for the Biotechnology average (which is currently at 0.0) sector and about the same as Price to Earnings To Growth (which currently averages 0.0) industry. This indicator is about the same for all United States stocks average (which is currently at 0.0).

Did you try this?

Run Transaction History Now

   

Transaction History

View history of all your transactions and understand their impact on performance
All  Next Launch Module

DiaMedica Fundamentals

About DiaMedica Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze DiaMedica Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of DiaMedica Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of DiaMedica Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota. Diamedica Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 14 people.

Pair Trading with DiaMedica Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if DiaMedica Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in DiaMedica Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving against DiaMedica Stock

  0.42SNDL SNDL Inc Buyout TrendPairCorr
The ability to find closely correlated positions to DiaMedica Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace DiaMedica Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back DiaMedica Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling DiaMedica Therapeutics to buy it.
The correlation of DiaMedica Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as DiaMedica Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if DiaMedica Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for DiaMedica Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether DiaMedica Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of DiaMedica Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Diamedica Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Diamedica Therapeutics Stock:
Check out DiaMedica Therapeutics Piotroski F Score and DiaMedica Therapeutics Altman Z Score analysis.
For information on how to trade DiaMedica Stock refer to our How to Trade DiaMedica Stock guide.
Note that the DiaMedica Therapeutics information on this page should be used as a complementary analysis to other DiaMedica Therapeutics' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

Complementary Tools for DiaMedica Stock analysis

When running DiaMedica Therapeutics' price analysis, check to measure DiaMedica Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy DiaMedica Therapeutics is operating at the current time. Most of DiaMedica Therapeutics' value examination focuses on studying past and present price action to predict the probability of DiaMedica Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move DiaMedica Therapeutics' price. Additionally, you may evaluate how the addition of DiaMedica Therapeutics to your portfolios can decrease your overall portfolio volatility.
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Money Managers
Screen money managers from public funds and ETFs managed around the world
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Is DiaMedica Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of DiaMedica Therapeutics. If investors know DiaMedica will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about DiaMedica Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(0.60)
Return On Assets
(0.30)
Return On Equity
(0.47)
The market value of DiaMedica Therapeutics is measured differently than its book value, which is the value of DiaMedica that is recorded on the company's balance sheet. Investors also form their own opinion of DiaMedica Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is DiaMedica Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because DiaMedica Therapeutics' market value can be influenced by many factors that don't directly affect DiaMedica Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between DiaMedica Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if DiaMedica Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, DiaMedica Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.